SynBiosys is an innovative biodegradable polymeric drug delivery system for the controlled release of small and medium-sized biologically active compounds. OctoPlus develops this technology in collaboration with InnoCore.

The system is based on a proprietary multiblock copolymer platform technology, which is designed to offer optimal control over drug release kinetics, thereby providing an improved therapeutic efficacy and fewer side effects. Physical and degradation characteristics can be easily adjusted, which allows the development of microsphere, film or implant formulations with adjustable sustained release for periods of 2 weeks up to 6 months. SynBiosys offers excellent opportunities to extend patent protection and upgrade current products.

Key attributes of SynBiosys are:

• Ideal delivery vehicle for small and medium-sized molecules, especially peptide drugs
• Controllable release profiles
• Linear to biphasic release
• 2 weeks to 6 months release
• Low initial burst release
• Drug loading of 1 to 30 wt%
• Based on biocompatible and regulatory approved building blocks
• Completely bioresorbable with adjustable degradation rate
• Integrity of the encapsulated drug maintained (absence of pH drop)
• Elastomeric properties
• Patent protected

OctoPlus has entered into a collaboration with InnoCore, the Netherlands, to develop and market this novel injectable drug delivery platform. The technology complements OctoPlus’ existing drug delivery platforms OctoDEX™ and PolyActive™. With these three platforms, OctoPlus is able to develop tailor-made controlled release formulations for all classes of injectable drug compounds.

For more information on the SynBiosys™ drug delivery system, please download our SynBiosys™ factsheet.